C12Y 207/01137
Phosphatidylinositol 3-kinase
Official title: Phosphatidylinositol 3-kinase (2.7.1.137)
C12Y207/01137 (Phosphatidylinositol 3-kinase) appears on 39 US grants and 62 published applications in this corpus.
Search patents in C12Y- Granted patents
- 39
- Published applications
- 62
- Assignees
- 37
- Inventors
- 121
- Latest grant
- 9 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 5 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 2 | 5 |
| 2004 | 0 | 3 |
| 2005 | 2 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 3 |
| 2011 | 1 | 1 |
| 2012 | 2 | 3 |
| 2013 | 2 | 1 |
| 2014 | 5 | 5 |
| 2015 | 3 | 2 |
| 2016 | 2 | 1 |
| 2017 | 2 | 8 |
| 2018 | 3 | 2 |
| 2019 | 1 | 2 |
| 2020 | 2 | 2 |
| 2021 | 1 | 5 |
| 2022 | 0 | 4 |
| 2023 | 0 | 4 |
| 2024 | 2 | 1 |
| 2025 | 2 | 2 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- T cell receptors targeting PIK3CA mutations and uses thereof9 Dec 2025US 12,492,237 B2Memorial Sloan Kettering Cancer Center
- PI3K inhibitors and uses thereof25 Nov 2025US 12,478,616 B2Sloan-Kettering Institute for Cancer Research
- Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide27 Aug 2024US 12,071,624 B2National Institutes of Biomedical Innovation, Health and Nutrition
- Methods and pharmaceutical compositions for treating lymphoid malignancy30 Apr 2024US 11,969,428 B2
- Selective PI3K delta inhibitors20 Apr 2021US 10,981,919 B2Rhizen Pharmaceuticals SA
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- T cell receptors targeting pik3ca mutations and uses thereof21 May 2026US 2026/0139026 A1Memorial Sloan Kettering Cancer Center
- Compositions and methods for immune cell modulation in adoptive cell therapy5 Feb 2026US 2026/0034216 A1Iyuda Therapeutics, LLC
- Use of p55-gamma gene and/or p55-gamma protein as target in maintaining cardiac iron homeostasis and treating related disease11 Sep 2025US 2025/0283058 A1Beijing Friendship Hospital, Capital Medical University
- Compositions and methods for inducing esr1, pi3k, her2, and her3 immune responses23 Jan 2025US 2025/0027110 A1Replicate Bioscience, Inc.
Most cited
By later US patents
- Inhibitors of human phosphatidyl-inositol 3-kinase delta138US 6,949,535 B2ICOS Corporation · 2005
- Inhibitors of human phosphatidylinositol 3-kinase delta135US 6,667,300 B2ICOS Corporation · 2003
- Antisense inhibition of PI3K p85 expression111US 6,100,090 AIsis Pharmaceuticals, Inc. · 2000
- Antisense modulation of PI3 kinase p110 delta expression53US 6,046,049 AIsis Pharmaceuticals, Inc. · 2000
- Inhibitors of human phosphatidylinositol 3-kinase delta46US 8,138,195 B2ICOS Corporation · 2012